Table 1 Patient demographics and baseline ocular findings in type1 CNV and type 2 CNV group
Characteristics. | Type 1 CNV group (n = 77) | Type 2 CNV group (n = 53) | p-value |
|---|---|---|---|
Age, years (mean ± SD) | 74.2 ± 7.2 | 76.6 ± 7.3 | 0.067 |
Sex, male/female (%) | 51/26 (66/34) | 29/24 (55/45) | 0.072 |
Lens status, phakic/pseudophakic (%) | 57/20 (74/26) | 33/20 (62/38) | 0.153 |
Best-corrected visual acuity, logMAR (mean ± SD) | 0.54 ± 0.30 | 0.75 ± 0.36 | 0.001 |
Central subfield retinal thickness, μm (mean ± SD) | 398.06 ± 123.07 | 436.74 ± 131.05 | 0.089 |
Subfoveal choroidal thickness, μm (mean ± SD) | 293.64 ± 79.97 | 229.32 ± 76.76 | < 0.001 |
Anti-VEGF, n (%) | Â | Â | 0.324 |
 Bevacizumab | 10 (13) | 5 (9) |  |
 Ranibizumab | 12 (15) | 12 (23) |  |
 Aflibercept | 39 (51) | 20 (38) |  |
 Mixed | 16 (21) | 16 (30) |  |
No. of intravitreal anti-VEGF injections (mean ± SD) | |||
 1 year | 7.0 ± 1.6 | 6.8 ± 1.4 | 0.436 |
 2 year | 5.1 ± 1.9 | 5.1 ± 1.4 | 0.940 |
 Total | 12.0 ± 3.0 | 11.8 ± 2.4 | 0.631 |
Fluid on OCT at baseline, n (%) | |||
 SRF | 77 (100) | 49 (92) | 0.014 |
 IRF | 2 (3) | 39 (74) | < 0.001 |